orforglipron · ORFORGLIPRON CALCIUM 2.5 mg/1 · Tablet, Film Coated · Oral · Eli Lilly and Company
NDC 00002-4503-31 · 1 BOTTLE in 1 CARTON / 30 TABLET, FILM COATED in 1 BOTTLE · NDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NCE | Apr 1, 2031 |
| exclusivity | NCE | Apr 1, 2031 |
| exclusivity | NCE | Apr 1, 2031 |
| exclusivity | NCE | Apr 1, 2031 |
| exclusivity | NCE | Apr 1, 2031 |
| exclusivity | NCE | Apr 1, 2031 |
| patent | RE50455 | Sep 26, 2037 |
| patent | RE50455 | Sep 26, 2037 |
| patent | RE50455 | Sep 26, 2037 |
| patent | RE50455 | Sep 26, 2037 |
| patent | RE50455 | Sep 26, 2037 |
| patent | RE50455 | Sep 26, 2037 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Eli Lilly and Company | ORFORGLIPRON CALCIUM 17.2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Eli Lilly and Company | ORFORGLIPRON CALCIUM 14.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Eli Lilly and Company | ORFORGLIPRON CALCIUM 5.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Eli Lilly and Company | ORFORGLIPRON CALCIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Eli Lilly and Company | ORFORGLIPRON CALCIUM .8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Eli Lilly and Company | ORFORGLIPRON CALCIUM 9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Lilly del Caribe, Inc. | ORFORGLIPRON CALCIUM 9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Lilly del Caribe, Inc. | ORFORGLIPRON CALCIUM .8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Lilly del Caribe, Inc. | ORFORGLIPRON CALCIUM 14.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Lilly del Caribe, Inc. | ORFORGLIPRON CALCIUM 17.2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Lilly del Caribe, Inc. | ORFORGLIPRON CALCIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Lilly del Caribe, Inc. | ORFORGLIPRON CALCIUM 5.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Italia S.r.l. | ORFORGLIPRON CALCIUM 5.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Italia S.r.l. | ORFORGLIPRON CALCIUM 17.2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Italia S.r.l. | ORFORGLIPRON CALCIUM .8 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Italia S.r.l. | ORFORGLIPRON CALCIUM 14.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Italia S.r.l. | ORFORGLIPRON CALCIUM 2.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Foundayo — NDC 00002-4503-31," retrieved September 3, 2026, https://drugdashboards.com/drug/00002450331.
Free to cite with attribution — see how the data is put together.